IL-2 pathway
Nektar Digs Into Mid-Stage Data To Establish Alopecia Efficacy of Rezpeg
Nektar Therapeutics; rezpegaldesleukin; Rezpeg; REZOLVE-AA; Phase 2b; alopecia areata; hair loss; SALT score; mid-stage trial; efficacy signal; Eli Lilly; IL-2 pathway; autoimmune disease; Phase 3 planning